Get the Stockscreener App
9.19
2.11%
0.19
Pre-market:
9.01
-0.18
-1.96%
Fennec Pharmaceuticals Inc stock is traded at $9.19, with a volume of 120.80K.
It is up +2.11% in the last 24 hours and down -5.74% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$9.00
Open:
$9.08
24h Volume:
120.80K
Relative Volume:
0.47
Market Cap:
$319.23M
Revenue:
$51.00M
Net Income/Loss:
$-8.73M
P/E Ratio:
-31.03
EPS:
-0.2962
Net Cash Flow:
$-7.75M
1W Performance:
+3.26%
1M Performance:
-5.74%
6M Performance:
+15.45%
1Y Performance:
+15.89%
1-Day Range:
$8.9512
$9.19
1-Week Range:
$8.515
$9.27
52-Week Range:
$5.65
$10.45
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
9.19 | 319.23M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals : Announces Results of Annual Meeting - marketscreener.com
New Fennec hire gets 10,000 stock options at $9, 10-year term - Stock Titan
FENC News | FENNEC PHARMACEUTICALS INC (NASDAQ:FENC) - ChartMill
Fennec Pharmaceuticals (FENC) Edges Higher as Biotech Sector Sees Mixed ActivitySector ETF Flow - newsline.com
Fennec Shareholders Approve Governance, Compensation and Equity Plans - TipRanks
FENNEC (NASDAQ: FENC) director receives fully vested options for 20,000 shares - Stock Titan
Fennec Pharmaceuticals (NASDAQ: FENC) director granted 20,000 stock options at $8.70 - Stock Titan
FENNEC (FENC) director Khalid Islam receives options on 25,000 shares - Stock Titan
FENNEC (FENC) director Chris Rallis receives fully vested option grant - Stock Titan
Fennec (NASDAQ: FENC) investors back directors, pay and new equity plans - Stock Titan
Fennec Pharmaceuticals (FENC) Faces Modest Pullback: Key Levels to WatchUp Down Volume - newsline.com
Fennec Announces Results of Annual Meeting - The Manila Times
Fennec investors re-elect directors, approve auditor and pay - Stock Titan
Technical Reactions to FENC Trends in Macro Strategies - Stock Traders Daily
Why Fennec Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Insider Favorites High Growth Companies June 2026 - simplywall.st
ASCO 2026 drives scientific collaboration for Fennec Pharmaceuticals in hearing loss prevention research - Traders Union
Fennec Pharmaceuticals (NASDAQ: FENC) director exercises options, sells shares for tax obligations - Stock Titan
Insider sale notice: Rostislav Raykov to sell 9,747 shares (FENC) - Stock Titan
Fennec Pharmaceuticals (FENC) CSO gains 156 vested shares in Form 4 filing - Stock Titan
Fennec Pharmaceuticals (FENC) CCO awarded 168 common shares in Form 4 - Stock Titan
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Fennec Pharmaceuticals (FENC) CEO receives 1,159-share stock award - Stock Titan
Fennec (NASDAQ: FENC) CFO gains 1,703 shares as prior awards vest - Stock Titan
Trading the Move, Not the Narrative: (FENC) Edition - Stock Traders Daily
Fennec Pharmaceuticals targets cisplatin-induced hearing loss with new survivorship research at ASCO26 - Traders Union
Fennec Pharmaceuticals Inc.Common Stock (NQ: FENC - FinancialContent
Fennec Pharmaceuticals (FENC) Gains 1.7% as Shares Bounce Off Support — Key Levels in FocusStandard Deviation - The Legal Advocate
Fennec Pharmaceuticals Drives PEDMARK Sales as Q1 Revenue Hits Peak - HarianBasis.co
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter - Yahoo Finance
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption By Investing.com - Investing.com Australia
Fennec Showcases New PEDMARK Data at ASCO 2026 - TipRanks
New PEDMARK studies at 2026 ASCO showcased by Fennec (NASDAQ: FENC) - Stock Titan
Maxim Group Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting - Moomoo
H.C. Wainwright Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Fennec Pharmaceuticals Announced New Research Supporting Integration and Use of PEDMARK at 2026 ASCO Annual Meeting - Moomoo
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting - The Manila Times
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of Pedmark - marketscreener.com
New cancer studies test PEDMARK to protect patients’ hearing - Stock Titan
(FENC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fennec Pharmaceuticals Grants Inducement Stock Options to New Employees Under Nasdaq Rule and Highlights PEDMARK®/PEDMARQSI® Commercialization Progress 1 - Minichart
(FRX) Strategic Market Analysis (FRX:CA) - Stock Traders Daily
Fennec (NASDAQ: FENC) issues 50,000 inducement stock options to new hires - Stock Titan
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fennec Pharmaceuticals : Corporate Presentation May 2026 - marketscreener.com
Three new Fennec hires get options on 50,000 shares at $9.75 - Stock Titan
Fennec Pharmaceuticals Inc Company Profile & Introduction - Moomoo
Fennec Pharmaceuticals(FENC) Stock Options Chain | Quotes & News - Moomoo
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Director |
Jun 01 '26 |
Sale |
9.62 |
9,747 |
93,766 |
130,079 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):